BR112017022255A2 - anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica - Google Patents
anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêuticaInfo
- Publication number
- BR112017022255A2 BR112017022255A2 BR112017022255A BR112017022255A BR112017022255A2 BR 112017022255 A2 BR112017022255 A2 BR 112017022255A2 BR 112017022255 A BR112017022255 A BR 112017022255A BR 112017022255 A BR112017022255 A BR 112017022255A BR 112017022255 A2 BR112017022255 A2 BR 112017022255A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- isolated
- vector
- producing
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Abstract
a presente invenção refere-se a anticorpos, em particular, anticorpos humanos ou humanizados, que se ligam ao domínio extracelular de receptor tyro3 humano, em particular, ao domínio do tipo imunoglobulina ig-1, e reduzem ou inibem a ligação de gas6 humano ao dito receptor. a invenção também se refere aos usos desses anticorpos no diagnóstico, na prevenção ou no tratamento de doenças hiperproliferativas ou infecciosas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305581 | 2015-04-17 | ||
PCT/EP2016/058457 WO2016166348A1 (en) | 2015-04-17 | 2016-04-15 | Anti-tyro3 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017022255A2 true BR112017022255A2 (pt) | 2018-08-28 |
Family
ID=52998002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017022255A BR112017022255A2 (pt) | 2015-04-17 | 2016-04-15 | anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica |
Country Status (8)
Country | Link |
---|---|
US (1) | US20180105596A1 (pt) |
EP (1) | EP3283523A1 (pt) |
JP (1) | JP2018512892A (pt) |
KR (1) | KR20170138494A (pt) |
CN (1) | CN108064245A (pt) |
BR (1) | BR112017022255A2 (pt) |
CA (1) | CA2982657A1 (pt) |
WO (1) | WO2016166348A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019328290A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
EP3844182A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
KR20210069639A (ko) | 2018-08-30 | 2021-06-11 | 에이치씨더블유 바이올로직스, 인크. | 단일-사슬 키메라 폴리펩타이드 및 이의 용도 |
CA3143035A1 (en) | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
US20210338724A1 (en) | 2020-02-11 | 2021-11-04 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
CN115362169A (zh) | 2020-02-11 | 2022-11-18 | Hcw生物科技公司 | 色谱树脂以及其用途 |
AU2021262794A1 (en) | 2020-04-29 | 2022-11-24 | HCW Biologics, Inc. | Anti-CD26 proteins and uses thereof |
KR20230031280A (ko) | 2020-06-01 | 2023-03-07 | 에이치씨더블유 바이올로직스, 인크. | 노화 관련 장애의 치료 방법 |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
CA2347066C (en) * | 1998-10-26 | 2011-05-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode t cell inducible factors (tifs), the proteins encoded, and uses thereof |
CA2385347C (en) | 1999-10-04 | 2009-12-15 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
ES2637801T3 (es) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
US20070098715A1 (en) * | 2005-03-25 | 2007-05-03 | Seth Ettenberg | Antibodies against the tenascin major antigens |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
EP2165710A1 (en) | 2008-09-19 | 2010-03-24 | Institut Curie | Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor |
HUE037159T2 (hu) * | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
BR112012027995A2 (pt) * | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
-
2016
- 2016-04-15 BR BR112017022255A patent/BR112017022255A2/pt not_active Application Discontinuation
- 2016-04-15 CN CN201680022536.0A patent/CN108064245A/zh active Pending
- 2016-04-15 US US15/565,950 patent/US20180105596A1/en not_active Abandoned
- 2016-04-15 JP JP2018505538A patent/JP2018512892A/ja active Pending
- 2016-04-15 EP EP16716610.7A patent/EP3283523A1/en not_active Withdrawn
- 2016-04-15 WO PCT/EP2016/058457 patent/WO2016166348A1/en active Application Filing
- 2016-04-15 KR KR1020177033168A patent/KR20170138494A/ko unknown
- 2016-04-15 CA CA2982657A patent/CA2982657A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016166348A1 (en) | 2016-10-20 |
JP2018512892A (ja) | 2018-05-24 |
CN108064245A (zh) | 2018-05-22 |
CA2982657A1 (en) | 2016-10-20 |
KR20170138494A (ko) | 2017-12-15 |
US20180105596A1 (en) | 2018-04-19 |
EP3283523A1 (en) | 2018-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017022255A2 (pt) | anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica | |
PH12017500819A1 (en) | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production | |
BR112018016697A2 (pt) | anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento. | |
BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
PH12017500890A1 (en) | Antibody drug conjugates | |
BR112017025693A2 (pt) | anticorpos anti-cd40 e seus usos | |
MX2021003436A (es) | Anticuerpos humanos para pd-1. | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
BR112016015140A2 (pt) | imunoglobulina com fabs in-tandem e usos das mesmas | |
MX2016012830A (es) | Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos. | |
BR112015017619A2 (pt) | formulação líquida, uso de uma formulação, e, kit | |
EA201792193A1 (ru) | Конструкции биспецифического антитела для cdh3 и cd3 | |
NZ703724A (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
EP3492101A3 (en) | Agents for influenza neutralization | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
BR112018072211A2 (pt) | anticorpos anti tl1a e utilizações dos mesmos | |
BR112013003257A2 (pt) | anticorpos egfr humanizados. | |
EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
BR112017007877A2 (pt) | anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado | |
IN2014DN09717A (pt) | ||
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
BR112017001097A2 (pt) | mioinositol e probióticos e seu uso | |
BR112016022508A2 (pt) | anticorpos contra hpa-1a | |
BR112018070452A2 (pt) | um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |